Core Viewpoint - cbdMD, Inc. announced the approval of the automatic conversion of its Series A Preferred Stock into Common Stock, which is expected to enhance its capital structure and eliminate significant dividend obligations [1][2]. Group 1: Shareholder Meeting Outcomes - Shareholders approved the automatic conversion of each share of Preferred Stock into thirteen shares of Common Stock, including all accumulated and unpaid dividends as of the Mandatory Exchange Date [1]. - The conversion is projected to eliminate approximately $6.7 million in accrued dividend payments as of March 31, 2025, and $4 million in annual dividend obligations, allowing the company to reinvest this capital into growth initiatives [2]. - Seven directors were elected for a term expiring at the 2026 annual meeting, Cherry Bekaert LLP was ratified as the independent registered public accounting firm, and an amendment for a reverse stock split was approved [2]. Group 2: Company Overview - cbdMD is recognized as a leading CBD company, offering a comprehensive line of THC-free CBD products and other brands such as Paw CBD, ATRx Labs, and Herbal Oasis [3]. - The company emphasizes its commitment to producing high-quality, U.S.-grown CBD products and aims to provide wellness-focused beverages through its Herbal Oasis brand [3].

cbdMD Achieves Key Milestone in UK Novel Food Regulatory ApprovalFSA Publishes Safety Assessment for cbdMD's Proprietary CBD IngredientApril 07, 2025 7:00 AM EDT | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - April 7, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leader in premium hemp-derived cannabidiol (CBD) products, proudly announces that its Novel Food dossier (RP793) has advanced to the last phase of regulatory assessment with the UK Food Standards Ag ...

Financial Data and Key Metrics Changes - Total net sales for Q1 fiscal 2025 were $5.1 million, a 12% increase from the prior year and a 12% increase from Q4 [12] - Gross profit remained at a healthy 66% for Q1 fiscal 2025 [13] - SG&A expenses decreased to $3.4 million from $4.6 million in the prior year [13] - The company achieved positive net income of $15,000 compared to a loss of $977,000 in Q1 fiscal 2024 [14] - Non-GAAP adjusted EBITDA was $214,000, a significant improvement from a loss of $698,000 in the prior year [14] Business Line Data and Key Metrics Changes - E-commerce direct-to-consumer sales were $3.9 million, a 10% year-over-year decrease, representing 77% of total net sales [12] - Wholesale business generated $1.1 million in net sales, up 22% compared to $950,000 in the prior year [12] Market Data and Key Metrics Changes - The beverage market is identified as the fastest-growing category within the CBD and hemp sectors, with significant growth observed in 2024 and continuing into 2025 [50][52] Company Strategy and Development Direction - The company is focused on achieving profitability and resolving capital structure challenges, with a clear roadmap for sustainable profitability [11][19] - New product launches, particularly in the Oasis social tonic line, are expected to drive future revenue growth [9][10] - The company is committed to enhancing its customer experience and optimizing its business operations [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's financial progress and the potential for future growth, emphasizing the importance of addressing capital structure to unlock shareholder value [19][25] - The company has transformed into a leaner organization focused on long-term success despite challenges in the hemp and CBD industry [26] Other Important Information - The company is now debt-free, excluding ordinary course liabilities and accrued dividends, which allows for better cash management [17] - A proposal for a conversion ratio of one to thirteen for Series A preferred stock is aimed at improving capital structure and regaining compliance with NYSE standards [23][24] Q&A Session Summary Question: Progress on Oasis Social Tonics - Management noted that the product has been well-received, though wholesale distribution is slower than expected due to legal document iterations [33] Question: DTC Margins for Oasis - DTC margins for Oasis are tighter than other products, but the channel remains viable with potential for profitable growth [36] Question: Revenue from Oasis in December Quarter - Some revenue was booked in the December quarter, but it was limited due to the short time frame [38] Question: Total Shares Outstanding Post-Conversion - Total shares outstanding as of February post-conversion are just over 6.2 million [41] Question: Liquidity Runway - Management maintains a positive outlook on liquidity, expecting to operate a positive EBITDA business [42][43] Question: Future Working Capital Needs - Management anticipates more normal working capital relationships in upcoming quarters [44]

cbdMD Generates $5.1 Million in Revenue, Positive EarningsFebruary 13, 2025 4:10 PM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - February 13, 2025) - (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the first quarter of fiscal year ended Decemb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 North Carolina 47-3414576 2101 Westinghouse Blvd., Suite A, Charlotte, NC 28273 Address of Principal Executive Offices Zip Code 704-445-3060 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Group 1 - cbdMD, Inc. will host a conference call on February 13, 2025, at 4:20 p.m. Eastern Time to discuss its financial results for the first quarter of fiscal year 2025, ending December 31, 2024 [1] - The company is recognized as one of the leading and most trusted CBD brands in the United States, offering a comprehensive line of THC-free CBD products [2] - cbdMD's product offerings include CBD tinctures, gummies, topicals, capsules, sleep aids, and drink products, as well as veterinarian-formulated pet products under the Paw CBD brand [2]

Core Viewpoint - cbdMD, Inc. has successfully satisfied its Senior Secured Convertible Notes, enhancing its financial position and becoming debt-free, excluding normal operational accounts payable [1][2]. Company Overview - cbdMD, Inc. is a leading and trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs [1][3]. - The company offers a comprehensive line of U.S. produced, THC-free CBD products, including tinctures, gummies, topicals, capsules, sleep aids, and drink products [3]. Financial Position - The full conversion of the Notes into common stock has strengthened the company's financial position, increased cash reserves, and provided greater flexibility for capital allocation [2]. - As of January 14, 2025, there are 6,262,833 shares of the company's common stock issued and outstanding [1].

cbdMD Announces Additional Conversions of Its Convertible NotesJanuary 08, 2025 5:22 PM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - January 8, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that the Company has reduced the principal amount outstanding on its Senior Secured Convertible Not ...

Company Compliance Issues - cbdMD received a notice from NYSE American on December 31, 2024, stating noncompliance with Section 1003(a)(i) of the NYSE American Company Guide due to stockholders' equity of $1,963,417 as of September 30, 2024, which is below the required $2 million [1] - The company reported losses from continuing operations and/or net losses in four of its five most recent fiscal years [1] - cbdMD remains subject to a compliance plan accepted by NYSE American on August 20, 2024, to address noncompliance under Section 1003(a)(ii) due to stockholders' equity under $4 million [2] - The company must regain compliance by December 5, 2025, or face delisting procedures [2] Stock Listing and Trading - The notice has no immediate impact on the listing of cbdMD's common stock (YCBD) or Series A Preferred Stock (YCBD-PA), which will continue to trade on NYSE American during the compliance plan period [3] - Both stocks will trade with the designation "BC" to indicate "below compliance" status [3] Financial Performance and Strategy - cbdMD reduced cash consumption from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024, with a significant reduction in the second half of fiscal 2024 [4] - The company is considering transactions, including converting Preferred Stock and its accrued dividend ($4.67 million as of September 30, 2024) into Common Stock, to increase stockholders' equity [4] Company Overview - cbdMD is a leading CBD company with brands including cbdMD, Paw CBD, and ATRx Labs, offering a comprehensive line of THC-free CBD products and Full Spectrum products [5][6] - The company's products include CBD tinctures, gummies, topicals, capsules, sleep aids, and Farm Act compliant Delta 9 products, as well as pet products and functional mushroom support [6]

cbdMD Announces Company's CEO Joins the Board of DirectorsDecember 23, 2024 3:52 PM EST | Source: cbdMDCharlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that T. Ronan Kennedy, the Company's Chief Executive Officer and Chief Financial Officer, has been ap ...